E. Schott

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Thomas Yau, J.W. Park, Richard S. Finn et al. · Annals of Oncology · 2019 · 648 citations · Full text

Medicine, Oncology, Pharmacology +12

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

Julia Dietz, S. Süsser, Johannes Vermehren et al. · Gastroenterology · 2017 · 151 citations

Life Sciences, Infectious Diseases, Microbiology +16

Association of <i>TLR7</i> single nucleotide polymorphisms with chronic HCV‐infection and response to interferon‐<i>a</i>‐based therapy

E. Schott, Heiko Witt, Konrad Neumann et al. · Journal of Viral Hepatitis · 2007 · 73 citations

Life Sciences, Immunology, Infectious Diseases +14

LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

Bruno Sangro, J. Park, Richard S. Finn et al. · Annals of Oncology · 2020 · 58 citations

Medicine, Oncology, Pharmacotherapy +13

Real‐world experience with the all‐oral, interferon‐free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry

Tania M. Welzel, Holger Hinrichsen, Christoph Sarrazin et al. · Journal of Viral Hepatitis · 2017 · 46 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16